The anime series xxxHolic and its sequels are based on Clamp’s manga series with the same name and were developed by Production I.G. It revolves around Kimihiro Watanuki, a high-school student disturbed by his ability to see the supernatural. He meets Yūko Ichihara, a powerful witch, who owns a wish-granting shop. Watanuki requests to have his ability to see spirits removed and as payment, Yūko hires him to work in the shop, resulting in his encounter with various supernatural adventures.
When I first stumbled upon this Anime I was pulled in by so many different qualities of the story. Between the real life examples of mystical rules of life to the humor, I quickly burned through a couple episodes everyday until sadly there was no more. BUT, there is another xxxholic I just couldn’t get into it. This version is my favorite and I’m sticking with it.
Enjoy xxxHolic,
You can see more Anime here.
1st Season of XXXHolic on DVD
Omnibus 1 XXXHolic Manga
-Nihon Scope
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Japan’s Chief Cabinet Secretary Yoshihide Suga unveils the name of new era “Reiwa” at the prime minister’s office in Tokyo, Monday, April 1, 2019. Japan says next emperor Naruhito’s era name is Reiwa, effective May 1 when he takes the throne from his father.(AP Photo/Eugene Hoshiko)
By Mari Yamaguchi
The name of the era of Japan’s soon-to-be-emperor Naruhito will be Reiwa, the government announced Monday.
Emperor Akihito is stepping down on April 30, in the first abdication in 200 years, bringing his era of Heisei to an end. The new era takes effect May 1.
The name draws from the 7th century poetry collection “Manyoshu,” Prime Minister Shinzo Abe said after the announcement by the chief cabinet secretary, Yoshihide Suga.
Abe said the name means that culture is born and grows when people come together and “care for each other beautifully.”
“With this selection of a new era name, I renew my commitment to pioneer a new era that will be filled with hope,” Abe said.
The Manyoshu is Japan’s oldest poetry collection and symbolizes Japan’s rich culture and long tradition, he said.
The choice was a break from more than 1,300 years of drawing era names, or gengo from using Chinese classics. It was kept strictly secret ahead of Monday’s announcement.
“We hope (the era name) will be widely accepted by the people and deeply rooted as part of their daily lives,” Suga told reporters in first announcing the name, written in two Chinese characters in black ink calligraphy on a white background.
JAPAN – 2nd Largest Pharma MarketBy Nitesh Bhele
Japan is the 2nd largest Pharmaceutical & biotechnology market in the world after the United States. Japan accounts for around 10 percent of the global pharma market, compared with 39 percent for the U.S. and 21 percent for Western Europe approximately. The pharmaceutical market has size around $ 150 billion, where biotechnology market value of Japan is projected to sharply increase reaching $100 billion by 2020. The Japan government recognized the big demand on this sector and realized the need of having a national strategy for Pharmaceutical & biotechnology development. Number of plans based on the Biotechnology Strategy Guidelines have been implemented since last few years.
Currently, Japan still lags behind the U.S. in this sector but it is taking a lead in the field of gene analysis, genetic recombination, bioinformatics and others. With the great effort of the government by providing substantial resources to this sector, biotechnology is expected to become a major sector. Furthermore, The Industrial Cluster Plan Policy is one of the efforts of the government to strengthen the capabilities of the defined regional cluster areas to develop new technologies and product. Among the 17 projects, 8 of them are focused on the biotechnology industries. Moreover, Japan has a much lower penetration of generics compared to most of the major markets which is advantageous for the big pharma.
In Japan, every citizen has to participate in the insurance program managed by Government of Japan National Health Insurance (NHI). National Health Insurance (NHI) scheme as well as the majority of health care spending is publically funded. The government is taking number of initiatives to control spending, such as encouraging use of cheaper generic drugs, self-management of chronic diseases, and preventive care. A biennial NHI pricing review usually results in price reductions. This also is one of the most significant challenges faced by pharmaceutical companies in the Japanese market is the practice of biennial price cuts. Overall, the average cut of 5.64% will be applied on a drug price basis in the 2014 price revisions similar to the price cut of 6% applied in the 2012 price revisions. Market expansion based re-pricing rules as well as the special additional price cut being implemented this year on products for which the first generic was approved five years ago and have less than 20% generic replacement rate by volume will hamper the growth of the domestic pharmaceutical industry In addition, a new health technology assessment (HTA), expected to be implemented in 2016, could make it more difficult for life sciences companies to obtain competitive launch pricing and market access unless the new treatment is deemed innovative and cost-effective. Also, while the use of cost-saving generic drugs has been proportionally lower in Japan than in other developed markets, the government has strengthened the incentives for healthcare providers to prescribe generics. The new drug development premium awarded to innovative products shields the products from biennial National Health Insurance (NHI) price reductions during their patent protection period. This premium will enable patented branded products in its market expansion. During the 2014 NHI price revisions, 397 active ingredients (758 products) have been granted the exemption, over and above the 367 active ingredients considered for the treatment in the 2012 revision.
(All statements made in this video/article does not reflect our personal interest or belief about pharmaceuticals here at Nihon Scope)
Takeda Pharmaceutical, Japan’s largest pharmaceutical company and Asia and a top 15 pharmaceutical company. The company has over 30,000 employees worldwide, looks likely to increase its global footprint merger & acquisition done by it all over world. Otsuka’s $3.5bn acquisition of California-based neurologic disease specialist Avanir Pharmaceuticals in December 2014 is an even more potent demonstration of Japanese companies’ greater focus on global M&A.
Indeed, generic manufacturers from around the world – but especially generic specialists such as India – are looking to Japan as a source of future expansion. According to the Economic Times, Indian generics giants including Dr Reddy’s, Lupin, Sun Pharma and Glenmark are exploring options for tapping into the growing Japanese generics market.
Active pharmaceutical ingredient (API) and generic finished dose suppliers who recognize this growth potential and understand the specific needs and challenges unique to the Japanese market stand to see significant earnings in this region over the coming years. The global Active Pharmaceutical Ingredient Market is expected to reach USD 205.51 billion by 2020 from USD 150 billion in 2015, at a CAGR of 6.5% during the forecast period .The active pharmaceutical ingredient (API) market in Asia is growing at an increasingly rapid pace. From 2007 to 2011, it went from 24.5 to 28.5 percent of the world market. From now through 2017, it should expand at a rate of 8.2 percent annually. This puts Asia’s API market worth $33 billion currently at more than $50 billion by 2017.
Japan has long led the rest of Asia in demand for APIs. In 2012, the market for APIs in Japan was the largest in Asia, at $15.5 billion. Many foreign API firms from India, Europe and the US are actively selling their APIs on the Japanese market. Japan’s share of innovator APIs is high, and demand is growing especially in the biotech drug sector. But API generics are also starting to gain ground in Japan. Chinese and Indian firms have recently flooded Japan’s market with inexpensive APIs. The accompanying price competition has forced some Japanese API manufacturers out of their own domestic market. An increasing number of foreign pharmaceutical companies are selling APIs on the Japanese market. Sometimes they sell to domestic drug manufacturers and sometimes they sell to foreign drug companies manufacturing products in Japan.
In April 2013, India’s Dishman Pharmaceuticals and Chemicals announced the company was on track to post an almost fivefold growth in revenue for APIs sold in Japan through the end of 2013. Revenue from Japanese sales reached $2 million in 2012, and 2013 revenue is expected to increase to $10 million. The company currently supplies APIs to more than 10 Japanese companies. In February 2012, Pfizer Japan launched two new APIs in Japan. One was part of the diabetes treatment glimepiride (Amaryl), while another was part of the antiarrhythmic agent pilsicainide (Sunrythum). Aside from these two APIs, Pfizer Japan launched another 16 APIs in Japan in 2012. If foreign API manufacturers pay attention to the Japanese API market, they will find excellent sales opportunities, especially in the innovative and generic API segments. Key market players Teva Pharmaceuticals limited (Israel), Sun Pharmaceuticals Industries Limited (India), Dr. Reddy’s Laboratories Ltd. (India), Aurobindo (India), Novartis International AG (Switzerland), Boehringer Ingelheim (Germany), Albemarle Corporation (U.S.), Sigma Aldrich (U.S.), Mylan (U.K.), Allergan plc. (Ireland). Stakeholders include Manufacturers of API Distributors and Suppliers of APIs, Potential Investors in the API Market, Pharmaceutical Companies, Biotechnology Companies, Contract Manufacturing Organizations and Healthcare Payers
According to Catenion’s , pharmaceutical industry of Japan faces two fundamental problems for which it has not yet found an answer; these problems are firstly, an inadequate approach to managing innovation and secondly, a profound misunderstanding of the nature of risk and consequently poor risk management. The industry’s poor innovation track record is shown by the statistics of drug approvals by the FDA. There has been a long-term trend of a decrease in the number of NCEs and NBEs despite rapidly increasing R&D budgets. A recent study by Czerepak and Ryser published in Nature Drug Discovery shows that for the period between January 2006 and December 2007, barely 35% of the drugs approved by the FDA originated in the pharmaceutical industry. Less than half of these qualified for the label “novel drug and new chemical structure”.
Industry critics have used statistics such as these to argue that Big Pharma is shying away from true innovation and pursuing mostly me-too projects. A quick look at company pipelines shows this to be a wrong conclusion. There is an abundance of exciting, highly innovative projects and risky science going on at most companies. While some industry observers and investors continue to hope there might be an innovation backlog in the wake of unprecedented progress in molecular biology, disease understanding, lab technologies and novel drug formats, others are more pessimistic.
Turning to the second issue, Catenion have identified, the pharmaceutical business is a risky business par excellence but the nature of risk is often not fully appreciated by operators. Of course pharmaceutical executives know the scientific, technical, regulatory and commercial risks of their business. They spend a lot of their time devising and executing risk mitigation activities for these risks at the operational level. The argument we wish to make here is that there is too little awareness that risk must be managed properly at the strategic level as well. Such strategic risk management requires more sophisticated methods than those generally used in the industry today. There are three major points to our argument, covering the nature of risk itself, correlated risk in the R&D pipeline and the degree of risk diversification at the corporate level.
(All statements made in this video/article does not reflect our personal interest or belief about pharmaceuticals here at Nihon Scope)
Lupin is the only Indian pharma company to have a presence in the Japanese generic market from which it currently earns about 12% of annual revenue. Till date, Lupin Ltd has made two buyouts in Japan: Tokyo-based I’rom Pharmaceutical Co. Ltd in 2011 and Kyowa Pharmaceutical Industry Co. Ltd in 2007. Sun Pharma, which acquired Ranbaxy Ltd for $4 billion last year, also plans to raise up to Rs.12,000 crore through convertible debentures or a qualified institutional placement (QIP) for expansion and acquisitions. Japan, where drug sales were estimated at $115 billion in 2013, accounts for nearly 10% of the global pharma market according to a 2014 Deloitte report. The growth will mainly come from higher generic penetration. The government is keen to have a larger generic share to reduce their healthcare costs. An ageing population and mounting health costs have prompted the Japanese government to try and increase the presence of generic drug makers, bringing the Japanese market under the radar of Indian pharmaceutical companies.
According to Deloitte report, Japan’s rapidly ageing population just over a quarter of the population was aged 65+ in 2013, up from 12% in 1990, and accounting for over 50% of the country’s healthcare costs is expected to drive demand for pharmaceuticals in 2014-2018.The state-funded National Health Insurance scheme covers every citizen in Japan. In 2010, as part of efforts to increase the generic penetration, the government launched a series of reforms targeting 30% of the drug market by 2014 and 60% by 2017, from 18% in 2010.
Besides the reported move by Sun Pharma, other Indian generics makers, including Dr Reddy’s Laboratories and Glenmark Pharmaceuticals Ltd, are exploring options for entering Japanese generics market with their formulation drugs.
By Nitesh Bhele, Pharmaceutical & Healthcare Marketer
Full article here – Page No 60
http://saffronmedia.in/eMagazin…/…/ISAApr01152016/index.html